Processing

Please wait...

Settings

Settings

Goto Application

1. WO2020140090 - ANTI-PD-L1 BINDING PROTEINS AND METHODS OF USE THEREOF

Publication Number WO/2020/140090
Publication Date 02.07.2020
International Application No. PCT/US2019/068826
International Filing Date 27.12.2019
IPC
A61K 39/395 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
C07K 16/18 2006.01
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
C07K 16/46 2006.01
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
46Hybrid immunoglobulins
C07K 19/00 2006.01
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
19Hybrid peptides
C12N 15/13 2006.01
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
11DNA or RNA fragments; Modified forms thereof
12Genes encoding animal proteins
13Immunoglobulins
CPC
C07K 16/2827
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
28against receptors, cell surface antigens or cell surface determinants
2803against the immunoglobulin superfamily
2827against B7 molecules, e.g. CD80, CD86
C07K 2317/33
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
2317Immunoglobulins specific features
30characterized by aspects of specificity or valency
33Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
C07K 2317/73
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
2317Immunoglobulins specific features
70characterized by effect upon binding to a cell or to an antigen
73Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
C07K 2317/76
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
2317Immunoglobulins specific features
70characterized by effect upon binding to a cell or to an antigen
76Antagonist effect on antigen, e.g. neutralization or inhibition of binding
C07K 2317/92
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
2317Immunoglobulins specific features
90characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
92Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Applicants
  • GIGAGEN, INC. [US]/[US]
Inventors
  • JOHNSON, David, Scott
  • ADLER, Adam, Shultz
  • MIZRAHI, Rena, Aviva
  • LIM, Yoong, Wearn
  • ASENSIO, Michael
Agents
  • HUBL, Susan, T.
Priority Data
62/785,66727.12.2018US
Publication Language English (EN)
Filing Language English (EN)
Designated States
Title
(EN) ANTI-PD-L1 BINDING PROTEINS AND METHODS OF USE THEREOF
(FR) PROTÉINES DE LIAISON ANTI-PD-L1 ET MÉTHODES D'UTILISATION DE CELLES-CI
Abstract
(EN)
Provided herein are antigen-binding proteins (ABPs) that selectively bind to PD-L1 and its isoforms and homologs, and compositions comprising the ABPs. Also provided are methods of using the ABPs, such as therapeutic and diagnostic methods.
(FR)
La présente invention concerne des protéines de liaison à un antigène (ABP) qui se lient de manière sélective à PD-L1 et ses isoformes et homologues, ainsi que des compositions comprenant les ABP. L'invention concerne également des méthodes d'utilisation desdites ABP, notamment des méthodes diagnostiques et thérapeutiques.
Latest bibliographic data on file with the International Bureau